Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOEBT1 who wrote (341)	6/20/2004 6:27:01 AM
From: Icebrg	Read Replies (2) of 590

Joe, >>Do you have any insight into intellectual properties rights to anti-CTLA4 relative to Pfizer and MEDX? >> No, I have no ideas about who controls what. Medarex does of course claim that they own the IP, while Pfizer doesn't have to bother yet to claim anything at this stage of the development. Neither of the companies seem to publicly acknowledge that there is a competitor working on what appears to be the same idea. Maybe they control different aspects of the technology. If they are successful I suppose they will have to sort this out one way or another. Or maybe Pfizer is the company to whom Medarex tries to license its IP. >> but Pfizer's results are better.>> I don't believe it is possible yet to claim that one set of results are better than another. The conditions surrounding the trials were not the same (they never are), so it is very difficult to compare what came out in the end. The positive things, as I see it, is that Pfizer appears to validate Medarex's approach. This approach appears to bring benefits to patients who should normally more or less have exhausted all treatment options. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next